# Testing the Addition of Radiation Therapy to the Immune Therapy Treatment for ES-SCLC

> **NCT06350162** · PHASE2 · UNKNOWN · sponsor: **Zhejiang Cancer Hospital** · enrollment: 100 (estimated)

## Conditions studied

- Extensive Stage Lung Small Cell Cancer

## Interventions

- **DRUG:** Serplulimab
- **RADIATION:** Chest Radiation

## Key facts

- **NCT ID:** NCT06350162
- **Lead sponsor:** Zhejiang Cancer Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-10-18
- **Primary completion:** 2024-12-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2024-04-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06350162

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06350162, "Testing the Addition of Radiation Therapy to the Immune Therapy Treatment for ES-SCLC". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06350162. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*